{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T05:39:05Z","timestamp":1792474745253,"version":"4.5.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CPD"],"published-print":{"date-parts":[[2026,10,15]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>Background: Pulmonary fibrosis (PF) is a progressive and fatal interstitial lung disease characterized\nby the depletion of alveolar epithelial cells (AECs) and the pathological accumulation of extracellular\nmatrix (ECM). Despite its high mortality rate, the molecular drivers of PF progression remain partially understood.\nRecent evidence suggests that pyroptosis, a pro-inflammatory programmed cell death, plays a pivotal\nrole in orchestrating the inflammatory cascade and fibrotic remodeling in the lung. Methods: This study\nemployed bibliometric and visual analysis via CiteSpace 6.2.4 to systematically map the research landscape of\npyroptosis in PF using the Web of Science Core Collection (2010-2025). Based on the identified hotspots, a\ncomprehensive review of the molecular activation pathways and cell-specific mechanisms was conducted.\nResults: Bibliometric analysis (Modularity Q=0.5381, Silhouette S=0.8236) revealed a significant shift in\nresearch focus from basic pathological descriptions (2010-2015) to detailed pyroptotic mechanisms (2015-\n2020), with immune checkpoint inhibitors emerging as the latest frontier since 2020. Mechanistically, we propose\nan \"Initiation-Amplification-Persistence\" model: AEC pyroptosis initiates epithelial barrier disruption;\nmacrophage pyroptosis amplifies the inflammatory storm and polarizes the immune microenvironment; and\nfibroblast activation sustains ECM deposition. Furthermore, we summarized potential therapeutic interventions,\nincluding small molecule synthetic compounds (Nintedanib, Pirfenidone, MCC950, VX-765, etc.), natural\nproducts (Lycorine, Tanshinone IIA, etc.) and biologically active substances (Canakinumab, Anakinra)\nthat exhibit multi-pathway synergistic effects. Conclusion: Targeting the pyroptosis signaling axis offers a\npromising strategy for reversing PF progression. Future research should prioritize the identification of pyroptosis-\nrelated biomarkers and the development of lung-targeted delivery systems to facilitate clinical translation\nand precision intervention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113816128503772261007160416","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T05:00:11Z","timestamp":1792472411000},"source":"Crossref","is-referenced-by-count":0,"title":["Decoding Pyroptosis in Pulmonary Fibrosis: Molecular Mechanisms and\nTherapeutic Horizons"],"prefix":"10.2174","volume":"32","author":[{"given":"Shuqi","family":"Zheng","sequence":"first","affiliation":[{"name":"College of Basic Medicine, Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region, 010110, China"},{"name":"Inner Mongolia Autonomous Region Hospital of Traditional Chinese Medicine, Hohhot, Inner Mongolia Autonomous Region, 010020, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlei","family":"Hua","sequence":"additional","affiliation":[{"name":"College of Basic Medicine, Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region, 010110, China"},{"name":"Inner Mongolia Autonomous Region Hospital of Traditional Chinese Medicine, Hohhot, Inner Mongolia Autonomous Region, 010020, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanze","family":"Feng","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Baotou Medical College, Baotou, Inner Mongolia Autonomous Region, 014040, China"},{"name":"Inner Mongolia Autonomous Region Hospital of Traditional Chinese Medicine, Hohhot, Inner Mongolia Autonomous Region, 010020, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengxia","family":"Liu","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Baotou Medical College, Baotou, Inner Mongolia Autonomous Region, 014040, China"},{"name":"Inner Mongolia Autonomous Region Hospital of Traditional Chinese Medicine, Hohhot, Inner Mongolia Autonomous Region, 010020, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibin","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Basic Medicine, Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region, 010110, China"},{"name":"Inner Mongolia Autonomous Region Hospital of Traditional Chinese Medicine, Hohhot, Inner Mongolia Autonomous Region, 010020, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Inner Mongolia Autonomous Region Hospital of Traditional Chinese Medicine, Hohhot, Inner Mongolia Autonomous Region, 010020, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuya","family":"Xilin","sequence":"additional","affiliation":[{"name":"Xilin Gol League Mongolian Medicine Hospital, Xilingol League, Inner Mongolia Autonomous Region, 026000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyang","family":"Yu","sequence":"additional","affiliation":[{"name":"College of Basic Medicine, Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region, 010110, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhui","family":"Li","sequence":"additional","affiliation":[{"name":"College of Basic Medicine, Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region, 010110, China"},{"name":"College of Pharmacy, Baotou Medical College, Baotou, Inner Mongolia Autonomous Region, 014040, China"},{"name":"Inner Mongolia Autonomous Region Hospital of Traditional Chinese Medicine, Hohhot, Inner Mongolia Autonomous Region, 010020, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113816128503772261007160416","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/259562\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113816128503772261007160416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T05:00:14Z","timestamp":1792472414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/259562\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113816128503772261007160416","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,15]]}}}